Credit Suisse’s Spero Therapeutics SPRO Stock Holding History

Credit Suisse’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13	Closed	–	–	4268
2022 Q2	$0	Buy	+13	New	+$38	﹤0.01%	4286

Other funds holding SPRO

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Credit Suisse's SPRO Position: Q3 2022 in Review

Credit Suisse sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 13 shares.

Credit Suisse first reported a position in SPRO in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

Credit Suisse reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 13 Spero Therapeutics shares in Q3 2022.
Credit Suisse first reported a position in Spero Therapeutics in Q2 2022 and held it in 1 quarter.
Credit Suisse's Spero Therapeutics position peaked at $0 in Q2 2022.
69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.